An audio replay will also be available shortly after the call and will remain so through March 16, 2009.
To access the replay, follow these instructions: Dial: 888-286-8010 (U.S.); 617-801-6888 (international) Participant Passcode: 44161634
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.
This press release contains forward-looking statements that reflect the
company's current views regarding the potential of the company's pipeline of
proprietary drug candidates, the value and potential of the company's
technology, and the company's financial position. These forward-looking
statements involve numerous risks and uncertainties, including but not limited
to: (i) the company's proprietary product candidates and those of its
collaboration partners are in various stages of clinical development and the
risk of failure is high and can unexpectedly occur at any stage of development
prior to regulatory approval for numerous reasons including safety and
efficacy findings; (ii) the timing or success of the commencement or end of
clinical trials and commercial launch of partnered products may be delayed or
unsuccessful due to slower th
|SOURCE Nektar Therapeutics|
Copyright©2009 PR Newswire.
All rights reserved